Theriva Biologics, Inc.
TOVX
$0.32
-$0.02-5.60%
AMEX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 35.83% | -88.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.45% | -71.01% | |||
| Operating Income | 25.45% | 71.01% | |||
| Income Before Tax | 54.23% | 66.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 54.23% | 66.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 54.23% | 66.60% | |||
| EBIT | 25.45% | 71.01% | |||
| EBITDA | 25.62% | 71.16% | |||
| EPS Basic | 73.42% | 76.69% | |||
| Normalized Basic EPS | 75.42% | 80.07% | |||
| EPS Diluted | 73.42% | 76.69% | |||
| Normalized Diluted EPS | 75.42% | 80.07% | |||
| Average Basic Shares Outstanding | 202.54% | 43.29% | |||
| Average Diluted Shares Outstanding | 202.54% | 43.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||